Dihydromyricetin (Dhm) for Liver Health

Research suggests that dihydromyricetin may offer protective effects for the liver in the context of alcohol-related damage, with one animal and cell-based study finding that DHM reduced liver fat accumulation, lowered triglyceride levels, decreased markers of liver injury, and appeared to work through multiple mechanisms including activation of a metabolic regulator called AMPK and suppression of inflammatory proteins. The available evidence on this specific topic consists of preclinical research conducted in mice and human liver cell models rather than human clinical trials, which is an important limitation when considering how these findings might translate to people. One additional study included in this review examined flavonoids as potential antiviral compounds using computer modeling and laboratory assays, but its findings are not directly relevant to DHM's effects on liver health. Overall, while the preclinical direction is supportive, the current body of evidence is narrow, and well-designed human trials would be needed to draw firmer conclusions about DHM's role in liver health.